Press releases

Innovative bioabsorbable coating is the first to complete absorption shortly after drug elution ends at three months.

Language update supports the strong safety profile for PROMUS Element and PROMUS Element Plus Stents.

PLATINUM Long Lesion clinical results presented at TCT 2012 show no heart attack or stent thrombosis at two-year follow-up.

Twelve-month data presented at TCT 2012 support safety and efficacy of Epic stent in iliac stenting.

Results presented on cost effectiveness and clinical benefits for older patients of the WATCHMAN® Left Atrial Appendage Closure Device; Lotus™ Aortic Valve System feasibility trial results reviewed.

Clinical presentations will provide new insights on Boston Scientific research in coronary and peripheral artery disease, including aortic valve disease and atrial fibrillation.

"We remain focused on executing our strategy to drive this organization back to revenue growth,” said CEO Hank Kucheman.

REPRISE II study results expected to support CE Mark and other regulatory filings.

Victory™ guidewires are designed to facilitate crossing of resistant lesions.

Pending addition of next generation mapping and navigation system would expand company portfolio into complex electrophysiology procedures.